Quick answer: A labeled milligram figure is a weight statement, and the buyer's real question is a weight of what. The solids in a lyophilized vial can include the peptide itself, associated counterions, residual moisture, formulation excipients, and other non-volatile process-related components. If the label refers to total material weight, the amount of peptide is lower than the labeled figure and cannot be read off the label at all. If it refers to net peptide content, the quantity is calculated so that the stated amount of peptide is present. Both conventions appear in commercial quotations. The procurement risk is not that one of them exists — it is that the basis goes undisclosed, is used inconsistently across documents, or does not match the agreed specification.
Procurement teams usually discover this the hard way. Two suppliers quote the same peptide, the same 10mg vial, and one price is meaningfully lower. The material arrives, and the analytical results do not line up. Nothing in either quotation was necessarily false. The two vials were defined on different bases.
This guide is written for procurement, QA, and formulation teams running qualified B2B projects. It is a specification and analytical-documentation reference. It does not establish that any material is sterile, endotoxin-controlled, pharmaceutical grade, suitable for injection, or approved for human use, and it does not provide dosing or medical guidance. Product-specific claims must be supported by the agreed specification and batch-linked test results.
1. Start with the composition, not the price
For procurement purposes, the measurable mass in a lyophilized vial is usually discussed in several major categories.
| Component | What it is | Why it is on the balance |
|---|---|---|
| Peptide | The target molecule, as defined by its sequence. | The thing the buyer is actually purchasing. |
| Counterions | The acid or base partners ionically associated with the peptide in its isolated salt form — commonly trifluoroacetate, acetate, or chloride. | A peptide is isolated as a salt. The counterion travels with it and has real weight. |
| Residual moisture | Water retained in the solid after drying. | Lyophilization reduces water; it does not remove all of it. |
| Formulation excipients | Bulking agents, stabilizers, or surfactants present in the formulation. | If they are present, they are part of the total solids in the vial. |
| Other process-related components | Residual solvents, inorganic or buffer salts, related peptide impurities, and other non-volatile process residues, where applicable. | They occupy mass even when they are not part of the intended product design. |
These categories do not necessarily add up to a clean analytical mass balance. Different tests use different methods, different reporting bases — as-is, dried, or anhydrous — and different uncertainties. The categories are a way to reason about where the weight goes, not an arithmetic identity.
Two labeling conventions are common in practice:
- Total-material-weight basis. The stated fill refers to the quantity of material dispensed. The actual peptide amount therefore cannot be established from the label alone and should be supported by an appropriate peptide-content determination on a clearly stated reporting basis.
- Net-peptide-content basis. The quantity is calculated so that the stated amount of peptide is present, with the supporting assay and calculation basis defined.
For projects where composition-equivalent comparison between suppliers matters, WUMO recommends defining both the quotation and the label on a net-peptide-content basis, because it is the only convention that makes two offers directly comparable. It can also be stated so that the labeled figure refers to peptide content only, excluding excipient weight. What it requires is that peptide content be measured and the basis declared, rather than assumed.
2. Purity percentage does not answer this question
The most common substitution in peptide sourcing is to read a purity figure as if it were a content figure. They are different measurements answering different questions.
| Result | What it describes | What it cannot establish |
|---|---|---|
| HPLC purity | The proportion of the target peak within the chromatogram, under a defined method, for the tested sample. | How much peptide is in the vial. It is an area-based composition result and does not enter a weight balance directly. |
| Mass spectrometry | Identity support through the expected molecular mass. | Purity percentage or content. |
| Peptide content assay | The amount of peptide present in the tested material, against a suitable reference standard and a defined calculation basis. | Chromatographic purity, or by itself the amount in each finished vial. |
| Moisture | Water retained in the solid, on a stated method. | Peptide amount, though it is part of the basis a content result is reported against. |
| Counterion content | The measured amount of the associated acid or base partner, on a stated method and basis. | Purity or identity. |
A material can be 99% pure by HPLC and still deliver less peptide than a buyer expected, because purity is measured within the chromatographic profile while counterion, water, excipients, and other residues sit outside it. Purity describes the quality of what is there. Content describes how much of it there is.
One thing this table rules out: you cannot obtain peptide content by subtraction. Taking 100% and deducting counterion, moisture, and excipients does not produce a valid content result. The individual figures may be reported on different bases, each carries its own uncertainty, and other non-volatile components may be present that no one has quantified. Content is measured, not inferred.
For how a content assay is actually run against a reference standard, see Purity vs Content. For the broader documentation review, see How Procurement, QA, and Formulation Teams Read Peptide COA, SDS, and Spec Sheets.
3. The counterion is not a rounding error
A synthetic peptide is normally isolated as a salt. Counterions are ionically associated with protonated or deprotonated sites in the isolated material — the termini and side chains that carry charge under the conditions of the process.
The measured counterion level is not something a buyer can compute from the sequence. It may depend on sequence, ionization state, purification history, exchange efficiency, residual acid, moisture, and the reporting basis used. That is exactly why it should be measured whenever counterion content materially affects the procurement specification, rather than estimated from a generic assumption.
Two practical consequences follow:
- Salt form changes the mass basis. The same peptide as a trifluoroacetate salt and as an acetate salt does not carry the same peptide mass per unit of material. A quotation that does not state the salt form has left a variable undefined.
- Counterion content is measurable. Counterion analysis is an established test, and its result can be reported on the COA with its method and basis. For how the salt form itself is specified, converted, and verified, see the companion guide: TFA-Removed Peptides and Salt Form.
4. Excipients are legitimate, and they are also weight
Lyophilized vials frequently contain excipients. Depending on the peptide and the presentation, a formulation may include a bulking agent such as mannitol, a stabilizer such as trehalose, or a surfactant such as polysorbate 80. These are included for real process reasons: to build a cake with mechanical structure, to protect the peptide in the solid state, or to reduce stress at interfaces.
Their presence is not a defect. Undisclosed weight is the problem.
Excipient levels are established from the required formulation concentration, cake structure, stabilization objective, vial configuration, and drying-cycle constraints — not from peptide mass alone. Two vial configurations may use the same excipient-to-peptide ratio, different ratios, or the same solution formulation filled at different volumes. The composition must be confirmed for the actual peptide and presentation rather than inferred from the labeled milligram amount.
Two questions make this reviewable:
- What excipients are in the formulation, and at what amount per vial?
- What is the total solids weight per vial, and does the labeled figure refer to peptide only or to total solids?
For the process reasons behind excipient choice and its effect on cake behavior, see Why Lyophilized Peptide Cakes Collapse.
5. The gap most buyers miss: assay result versus amount per vial
This is the part that decides whether a "net peptide content" claim is real, and it is where most sourcing conversations stop one step too early.
A peptide-content result on a COA describes the material that was tested. A per-vial claim describes what ended up in each container. They are connected, but one does not automatically establish the other.
Bridging the gap requires, in addition to the assay:
- the assay result and reporting basis actually used in the formulation calculation;
- the solution concentration prepared from that material;
- the target fill volume or fill weight per vial;
- the dispensing controls applied during filling;
- the applicable fill-uniformity or weight-check records for the batch.
So a buyer asking "can you confirm the actual net peptide content per vial?" is really asking three separate questions, and they are worth separating in an RFQ:
| The question | What answers it |
|---|---|
| How much peptide is in the material? | A peptide-content assay on the tested material, with method, reference standard, and reporting basis stated. |
| How much peptide is each vial designed to contain? | The formulation calculation: assay basis used, solution concentration, and target fill. |
| Is that target actually delivered, vial to vial? | Dispensing controls and fill-uniformity or weight-control records for the batch. |
A supplier who answers only the first question has given you a real result that does not yet support a per-vial claim. A supplier who can walk through all three is describing a controlled process.
Illustrative calculation only
Assume a supplier has independently established that a material contains 87.0% peptide on an as-is mass basis. To target 10.0 mg of peptide:
10.0 mg ÷ 0.870 = 11.49 mg of material
This is an arithmetic illustration, not a manufacturing instruction, an industry-typical figure, or a substitute for batch-specific formulation and filling controls. The applicable assay result, reporting basis, solution preparation, fill controls, and acceptance criteria must all be defined for the actual project. The 87.0% is a made-up number chosen to show the arithmetic; it represents no batch, product, or industry norm.
6. The COA and manufacturing records needed to reconcile the label
For projects where the mass basis matters, the following analytical results describe the composition of the tested material. They can be tested and reported when the project defines them.
| COA field | What it answers |
|---|---|
| Peptide content | How much peptide is present in the tested material, on a stated method and calculation basis. |
| Counterion content | How much of the mass belongs to the associated salt partner. |
| Residual solvent, including residual TFA where applicable | Whether purification residues remain, and at what measured level. |
| Moisture | How much water the solid retains, on a stated method. |
These fields establish composition. They do not by themselves prove the net peptide amount in every finished vial — that also depends on the formulation calculation, fill target, and dispensing controls described in the previous section.
Two points of discipline apply to how a buyer should read any of it:
- Available on request is not the same as included by default. These are project-defined tests, not automatic entries on every catalogue COA. State them in the RFQ so the supplier can confirm scope and any effect on price and lead time before quotation.
- A result belongs to a lot. A representative example document supports a discussion. A batch-linked COA supports a release decision. If a document is representative rather than lot-specific, the supplier should say so plainly.
7. What to write in the RFQ
The following fields turn this from a post-delivery dispute into a pre-quotation specification.
| RFQ field | What to state |
|---|---|
| Labeling basis | Whether the labeled milligram figure refers to net peptide content or to total material weight. |
| Excipient treatment | Whether the labeled figure excludes excipient weight, and whether excipients are acceptable in the project at all. |
| Salt form | The required counterion, or that the supplier should state the form actually supplied and support it analytically. |
| Required COA fields | Peptide content, counterion content, residual TFA where applicable, moisture, each with method and reporting basis. |
| Per-vial basis | Whether a per-vial net peptide claim is required, and what formulation and fill-control evidence supports it. |
| Batch linkage | Whether documents must be batch-specific rather than representative. |
| Quote unit | Whether the price is per vial, per gram of total material, or per gram of peptide content. |
The last row is where the money is. A price per gram of total material and a price per gram of peptide content are different numbers for the same shipment. Normalize the quotations to peptide content before deciding which offer is lower.
8. Red flags worth pausing on
None of these disqualifies a supplier. Each is a reason to ask one more question before a deposit.
- The supplier cannot say whether the labeled amount refers to peptide content or total material weight.
- Purity percentage is offered in place of a content result.
- A per-vial net peptide claim is made with no formulation or fill-control basis behind it.
- Salt form is absent from the quotation, the specification sheet, and the COA.
- Excipients are present in the formulation but do not appear in any document.
- A content, counterion, or moisture figure is quoted with no method, no reporting basis, and no lot linkage.
- A document cannot be matched to the batch being supplied.
Frequently Asked Questions
Does a vial labeled 10mg contain 10mg of peptide?
It depends on the labeling basis. On a total-material-weight basis, the figure refers to the quantity of material dispensed, which also carries counterion, residual moisture, excipients, and other process-related components; the peptide amount cannot be read from the label. On a net-peptide-content basis, the quantity is calculated so that 10mg of peptide is present. Confirm which basis applies before comparing prices.
Is peptide content the same as HPLC purity?
No. HPLC purity describes the proportion of the target peak within the chromatogram under a defined method. Peptide content describes how much peptide is present in the tested material, and requires a suitable reference standard and a stated calculation basis. A high purity percentage does not establish content.
Can peptide content be calculated by subtracting counterion, moisture, and excipients?
No. The individual results may be reported on different bases, each carries measurement uncertainty, and other non-volatile components may be present and unquantified. Content should be determined by an appropriate assay on a clearly stated reporting basis, not by difference.
Does a peptide-content result on a COA prove how much peptide is in each vial?
Not on its own. The assay describes the material that was tested. A per-vial claim additionally depends on the assay basis used in the formulation calculation, the solution concentration, the target fill, the dispensing controls, and the applicable fill-uniformity or weight-control records. Buyers should ask for all three layers when a per-vial claim matters.
What is counterion content, and why does it appear on a COA?
A synthetic peptide is isolated as a salt, so acid or base partners are ionically associated with its charged sites. Counterion content is the measured amount of that partner. It appears on a COA because it occupies part of the mass and therefore affects how a labeled figure should be read. Its level depends on sequence, ionization state, purification history, exchange efficiency, residual acid, moisture, and reporting basis, so it is measured rather than calculated from the sequence.
Can a supplier label a vial by peptide content only, excluding excipients?
Yes, this can be specified. The labeled figure can be defined to refer to peptide content alone, with excipient weight excluded, provided peptide content is measured, the formulation and fill basis are defined, and all of it is stated in the specification and the COA rather than assumed.
Why do excipients appear in a lyophilized peptide vial?
Excipients such as mannitol, trehalose, or polysorbate 80 may be used to build cake structure, stabilize the peptide in the solid state, or reduce stress at interfaces. Which are used, and at what level, is established from the formulation concentration, cake structure, stabilization objective, vial configuration, and drying cycle, not from the peptide mass alone.
How should two quotations be normalized before comparison?
Confirm the labeling basis, salt form, excipient treatment, per-vial evidence, and document scope for both offers, then convert both prices to the same unit — ideally price per gram of peptide content. A lower price per vial may simply reflect a different definition of what the vial contains.
Does a low residual moisture result guarantee stability?
No. Residual moisture is one contributing factor among several, alongside temperature, formulation, packaging, and the properties of the specific peptide. It should be read as one result within a batch document package, not as a standalone stability guarantee.
Define the basis before you compare the price
If your team is specifying a lyophilized peptide vial project, state the labeling basis, salt form, excipient treatment, required COA fields, and whether a per-vial net peptide claim is needed. WUMO can confirm what the applicable method, formulation approach, and current batch can support before issuing a formal quotation.